Similar articles

• [Canavan disease (aspartoacylase deficiency)].

  Kobayashi K, Sakuragawa N. Kobayashi K, et al. Ryoikibetsu Shokogun Shirizu. 1998;(18 Pt 1):385-8. Ryoikibetsu Shokogun Shirizu. 1998. PMID: 9590077 Review. Japanese. No abstract available.
• Upregulation of N-acetylaspartic acid resulting nitric oxide toxicity induces aspartoacylase mutations and protein interaction to cause pathophysiology seen in Canavan disease.

  Surendran S. Surendran S. Med Hypotheses. 2010 Dec;75(6):533-4. doi: 10.1016/j.mehy.2010.07.017. Epub 2010 Jul 31. Med Hypotheses. 2010. PMID: 20673702
• Novel splice site mutation of aspartoacylase gene in a Turkish patient with Canavan disease.

  Rady PL, Penzien JM, Vargas T, Tyring SK, Matalon R. Rady PL, et al. Eur J Paediatr Neurol. 2000;4(1):27-30. doi: 10.1053/ejpn.1999.0256. Eur J Paediatr Neurol. 2000. PMID: 10701101
• Homozygosity for mutation G212A of the gene for aspartoacylase is associated with atypical form of Canavan's disease.

  Velinov M, Zellers N, Styles J, Wisniewski K. Velinov M, et al. Clin Genet. 2008 Mar;73(3):288-9. doi: 10.1111/j.1399-0004.2007.00934.x. Epub 2007 Dec 6. Clin Genet. 2008. PMID: 18070137 No abstract available.
• Recent advances in Canavan disease.

  Matalon R, Michals-Matalon K. Matalon R, et al. Adv Pediatr. 1999;46:493-506. Adv Pediatr. 1999. PMID: 10645473 Review.